Helping patients reclaim a life of possibility
Last week Myeloma Patients Europe (MPE) submitted a response to the European Medicines Agency (EMA) open consultation on their “Reflection paper on patient experience data (PED)”. PED refers to data from patients that includes their perspectives, preferences and experiences with different aspects of their disease and treatments, such as quality of life and risk tolerability,…
Myeloma patients may receive many different treatments throughout their care. Patients’ real-world experiences of treatments tell us how treatments work in everyday life. Myeloma Patients Europe (MPE) wants to hear from myeloma patients about their experiences with some particular treatments: Bispecific antibodies (such as teclistamab or elranatamab) CAR T-cell therapy (such as cilta-cel or ide-cel) Antibody–drug conjugates (such as…
The US Food and Drug Administration (FDA) has issued draft guidance to the pharmaceutical industry on using minimal residual disease (MRD) and complete response (CR) in myeloma clinical trials as a primary endpoint, to support approval under accelerated assessment. This follows a previous decision of the US FDA’s Oncology Drugs Advisory Committee (ODAC) to accept…
The largest haematology meeting in the world has just finished. The American Society of Hematology (ASH) Annual Congress took place in Orlando, Florida, US, where the latest research in blood diseases was presented. Myeloma Patients Europe (MPE) interviewed key experts to learn more about the most relevant studies and abstracts in myeloma and AL amyloidosis.…
From 6-9 December Myeloma Patients Europe (MPE) attended the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. Over 20,000 researchers, doctors, nurses and patient advocates attended the meeting to share and discuss the results of the latest research from across blood cancers. ASH was a great way to close out another successful year…
We are delighted to share MPE’s Year in Review 2025, a summary of what we have achieved this year alongside our many collaborators. This year we have strengthened partnerships, welcomed new members into our community and made progress on the European advocacy issues that matter most to patients and their families. We have worked together…
On 15 November, MPE member organisation AF3M (the French Association of Myeloma Patients) held its 20th National Myeloma Day across 28 cities in France, including La Réunion Island. This remarkable milestone event brought together patients and carers for information and discussion, organised in collaboration with AF3M’s longstanding partner IFM (Intergroupe Francophone du Myélome), whose research…
Despite war-related damage to its original venue, MPE member organisation AMEN Israel brought together leading haematologists and patients to explore pathways to curing myeloma in a memorable 20th anniversary conference. AMEN Israel, MPE’s member organisation in Israel and the country’s myeloma patient association, marked a significant milestone this year with its 20th anniversary conference. What…